Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Touts Compliance Program In Letter To Sen. Grassley

Executive Summary

Abbott believes its ethics and compliance program is "admirable," the company told Senate Finance Committee Chairman Charles Grassley (R-Iowa)

You may also be interested in...



Abbott Avoids Compliance Requirements In Kos Off-Label Marketing Settlement

A $41 million settlement of kickback and off-label marketing allegations involving Kos Pharmaceuticals’ cholesterol drugs will not result in new compliance requirements for parent company, Abbott Laboratories.

Abbott Avoids Compliance Requirements In Kos Off-Label Marketing Settlement

A $41 million settlement of kickback and off-label marketing allegations involving Kos Pharmaceuticals’ cholesterol drugs will not result in new compliance requirements for parent company, Abbott Laboratories.

Vioxx Hearing May Be Sign Of Things To Come Under Medicare Rx

The Senate Finance Committee should continue to review FDA's drug safety procedures in light of the upcoming expansion of the Medicare program, Ranking Democrat Max Baucus (D-Mont.) maintained during the committee's Nov. 18 hearing on Vioxx

Related Content

Topics

UsernamePublicRestriction

Register

PS044660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel